Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

516
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
516
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

343
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
343
Angina IV: Management01:26

Angina IV: Management

366
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
366
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.6K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.6K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

815
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
815
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

433
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
433

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effect of Intravenous Administration of Alprostadil on Circulating Microvesicles in Patients with Chronic Limb-Threatening Ischemia (CLTI): A Preliminary Study.

Journal of clinical medicine·2026
Same author

Determinants of In-Stent Restenosis in ST-Elevation Myocardial Infarction: Insights from a Single-Center Retrospective Analysis.

Medicina (Kaunas, Lithuania)·2026
Same author

MicroRNA profiles in multiple sclerosis: A review of the literature.

Journal of neuroimmunology·2026
Same author

Cardiovascular Involvement in Systemic Lupus Erythematosus: Focus on Arrhythmias.

Diagnostics (Basel, Switzerland)·2026
Same author

Post-COVID-19 Muscle Weakness and Recovery Patterns After Mild-to-Moderate Infection: A Retrospective Analysis of a Structured Rehabilitation Program Using the MRC Scale.

Healthcare (Basel, Switzerland)·2026
Same author

Arrhythmias in Systemic Sclerosis: A Call for Interdisciplinarity Teams.

Life (Basel, Switzerland)·2025

Related Experiment Video

Updated: Feb 28, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.4K

In-Stent Restenosis Pathophysiology and Risk Factors: A Comprehensive Review.

Alice Elena Munteanu1,2, Alexandru Andrei Badea3, Alexandru Mihai Popescu3

  • 1Department of Cardiology, 'Carol Davila' Central Military Emergency University Hospital, 010825 Bucharest, Romania.

Medicina (Kaunas, Lithuania)
|February 27, 2026
PubMed
Summary

In-stent restenosis (ISR) is a complex issue after stenting, driven by neointimal hyperplasia and neoatherosclerosis. Understanding its mechanisms and risk factors is key for effective patient management and preventing recurrent ischemia.

Keywords:
acute coronary syndromebare-metal stentdrug-eluting stentendothelial dysfunctionin-stent neoatherosclerosisin-stent restenosisneointimal hyperplasiapercutaneous coronary interventiontarget lesion revascularizationvascular smooth muscle cells

More Related Videos

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

14.4K
Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

4.9K

Related Experiment Videos

Last Updated: Feb 28, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.4K
Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

14.4K
Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

4.9K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • In-stent restenosis (ISR) is a significant cause of recurrent ischemia and repeat revascularization, despite advances in stent technology.
  • While drug-eluting stents (DESs) have reduced restenosis rates compared to bare-metal stents (BMS), ISR remains a long-term concern with poorer outcomes than percutaneous coronary intervention (PCI) for de novo lesions.

Purpose of the Study:

  • To review the current evidence on the biology, risk factors, and management of in-stent restenosis.
  • To support risk stratification, preventive strategies, and individualized treatment approaches for ISR.

Main Methods:

  • Synthesis of current evidence on ISR biology and risk factors.
  • Review of mechanistic insights into ISR, including neointimal hyperplasia and neoatherosclerosis.
  • Discussion of clinical presentation, patient-level, and lesion/procedural risk determinants.

Main Results:

  • ISR is a time-dependent, heterogeneous process involving neointimal hyperplasia early and neoatherosclerosis later.
  • Key patient risk factors include diabetes, chronic kidney disease, dyslipidemia, hypertension, and smoking.
  • Lesion/procedural factors include small vessels, complex lesions, multiple stents, and suboptimal expansion.
  • Intravascular imaging (OCT/IVUS) is crucial for phenotyping ISR mechanisms and guiding therapy.

Conclusions:

  • ISR requires prompt recognition and mechanism-informed management, often presenting as acute coronary syndrome (ACS).
  • Risk stratification based on patient and procedural factors is essential.
  • Intravascular imaging aids in tailoring prevention and treatment strategies for ISR.